Results 121 to 130 of about 7,833 (210)

BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Lambda immunoglobulin light chain (AL) amyloidosis associated with non‐IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited. Methods Here we describe the case of a patient with a history of LPL‐associated AL amyloidosis who had previously
Nadia Al Haddad, Eugene Brailovski, Jacqueline Dela‐Pena, Melinda Cook, Michael Rosenzweig, Heather Jolie Landau   +5 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

MedComm, Volume 7, Issue 6, June 2026.
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele, Ajit Manchare, Swapnali Parit, Amol D. Gholap, Krishna Jadhav, Navnath Hatvate, Keshav Raj Paudel, Satish Rojekar   +7 more
wiley   +1 more source

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

, 2019
Aberrant activation of Bruton’s tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological malignancies.
Nan Hu (4067), Fan Wang (135182), Wei Li (7081), Xuesong Liu (614293), Steve Young (6707126), Dan Su, Yunhang Guo, Wei Zhang (405), Xiaomin Song, Steve Young, Bo Zhang (6559), Zhiyu Tang (7275425), Shuaishuai Chen (7275431), Zhijian Sun, Changyou Zhou (2490022), Dan Su (8007), Gongyin Shi, Zhiyu Tang, Qiang Wei, Ye Liu (296340), Lusong Luo (2052394), Wei Li, Guodong Liu (278986), Yuan Hong (413401), Guodong Liu, Yin Guo (113948), Shuo Zhang, Shuo Zhang (30844), Zhenzhen Cheng (7275434), Dongping Zhou (7275440), Libin Liu (144204), Desheng Yu, Lei Lv, Huipeng Song, Yunhang Guo (7275416), Huipeng Song (7275428), Libin Liu, Haimei Xing (7275437), Gongyin Shi (7275422), Na Li (6550), Changyou Zhou, Qiuwen Wang, Zhiwei Wang (120259), Lai Wang (23747), Min Wei, Zhiwei Wang, Haisheng Wang (1434631), Xuesong Liu, Desheng Yu (7275419), Xing Zhou (469137), Nan Hu, Junhua Liu, Shuaishuai Chen, Zhongbo Wang, Qiang Wei (187077), Min Wei (77168), Haipeng Xu, Junhua Liu (1570747), Haisheng Wang, Fan Wang, Zhongbo Wang (6094562), Wei Zhang, Lai Wang, Xiaomin Song (1677622), Haipeng Xu (2407237), Yin Guo, Haimei Xing, Dongping Zhou, Hanzi Sun (648677), Xing Zhou, Hanzi Sun, Lei Lv (169816), Bo Zhang, Zhijian Sun (4218202), Ye Liu, Lusong Luo, Zhenzhen Cheng, Yuan Hong, Na Li, Qiuwen Wang (1584481)   +79 more
core   +1 more source

Use of biomolecular emulator for characterizing flexible proteins by small‐angle x‐ray scattering

Protein Science, Volume 35, Issue 6, June 2026.
Abstract Flexible proteins populate heterogeneous conformational ensembles that are essential for their function. Small‐angle x‐ray scattering (SAXS) is widely used to study protein structure in solution and to characterize conformational heterogeneity.
Yoni Haitin, Bar Manori, Moshe Giladi
wiley   +1 more source

Breaking Barriers Between Species: Integrated Multi‐Species PK Models Improve Human PK Predictions

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 6, June 2026.
ABSTRACT The accurate prediction of human pharmacokinetics (PK) is critical for compound selection and determining the human efficacious dose in drug discovery. Besides predicting the key PK parameters clearance (CL) and steady‐state distribution volume (Vss), the prediction of exposure metrics, e.g., maximum and trough concentrations (Cmax, Ctrough ...
Miriam S. R. Happ, Jens M. Borghardt, Charlotte Kloft, Hermann Rapp, Achim Sauer, Anneke Himstedt, Bettina Gerner   +6 more
wiley   +1 more source

Molecular Dynamic Simulation data of compensatory mutations in Bruton's Tyrosine Kinase

, 2019
The research aims to find compensatory mutations that rescue Bruton’s tyrosine kinase (Btk) activity in the presence of severe X-linked agammaglobulinemia (XLA) causing mutation in the kinase domain. The data set includes the molecular dynamic simulation
Nikita Chopra (2580964), Amy H. Andreotti (366314), Kejue Jia (8102966), Robert Jernigan (23908)   +3 more
core   +1 more source

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

British Journal of Haematology, Volume 208, Issue 6, Page 2059-2068, June 2026.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, Gianmarco Favrin, Emanuele Cencini, Alessandro Noto, Irene Dogliotti, Jacopo Olivieri, Marcello Riva, Isacco Ferrarini, Anna Maria Barbui, Sara Steffanoni, Dario Marino, Benedetta Puccini, Piero Maria Stefani, Rita Rizzi, Michele Merli, Angela Ferrari, Stefano Luminari, Carlo Visco, Livio Trentin, Andrea Visentin, Annarita Conconi, Simone Ferrero, Marzia Varettoni, Alessandra Tedeschi, Luca Laurenti, Francesco Piazza   +27 more
wiley   +1 more source

Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMA

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Expedited pathways in the United States (U.S.), European Union (EU), and Japan (JP) enable earlier access to innovative therapies for rare and serious diseases. In 2025, Japan explicitly introduced revocation provisions to its Conditional Early Approval (CEA).
Takahiro Handa, Arata Tanaka, Mayumi Shikano, Rika Wakao   +3 more
wiley   +1 more source

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 845-849, June 2026.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source